期刊文献+

3,5-二烷基-4-羟基苯甲腈的一步法合成 被引量:1

ONE-POT SYNTHESES OF 3,5-DIALKYL-4-HYDROXYBENZONITRILES
下载PDF
导出
摘要 实验以3,5-二烷基-4-羟基苯甲醛(烷基为甲基、异丙基和叔丁基)和NH2OH.HCl为原料,在HCOOH、HOAc和DMF 3种溶剂中一步法合成相应的苯甲腈。考察了原料配比、反应温度等对产物收率的影响。结果表明,合成3,5-二甲基-4-羟基苯甲腈的最优条件为:醛用量0.16 mol,n(醛)∶n(羟胺)=1∶1.2,DMF用量80 mL,温度105℃,反应6 h,收率93.5%;合成3,5-二异丙基-4-羟基苯甲腈的较优条件为:n(醛)∶n(羟胺)=1∶1.2,DMF用量100 mL,温度105~110℃,反应6 h,收率88.0%;合成3,5-二叔丁基-4-羟基苯甲腈的较优条件为:n(醛)∶n(羟胺)=1∶1.2,HOAc用量100 mL,温度105~110℃,反应6 h,收率99%以上。 The one-pot syntheses of 3,5-dialkyl-4-hydroxybenzonitriles (alkyl= methyl, isopropyl and tert-butyl) from the corresponding benzaldehydes and NH2 OH - HCl in HCOOH, HOAc, and DMF, respectively, were pyl-4-hydroxybenz 99%, respectively studied. The highest yields of 3,5-dimethyl-4-hydroxybenzonitrile, 3,5-di-isopro- onitrile and 3, 5-di-tert-butyl- 4-hydroxybenzonitrile were 93.5%, 88.0% and , under optimal conditions.
出处 《精细石油化工》 CAS CSCD 北大核心 2010年第3期48-51,共4页 Speciality Petrochemicals
关键词 3 5-二烷基-4-羟基苯甲醛3 5-二烷基-4-羟基苯甲腈 苯甲腈 盐酸羟胺 3, 5-dialkyl-4-hydroxybenzonitrile 3, 5-dialkyl-4-hydroxybenzonitriles benzonitrile hydroxyamine hydrochloride
  • 相关文献

参考文献22

二级参考文献67

  • 1曲虹琴,赵冬梅,程卯生.新型非甾体抗炎药darbufelone mesilate的合成工艺研究[J].中国药物化学杂志,2004,14(5):298-300. 被引量:3
  • 2陈先红,谢蓝.抗耐药性HIV非核苷类逆转录酶抑制剂的研究进展[J].中国药物化学杂志,2006,16(3):182-187. 被引量:4
  • 3田金如,聂新永,李永伟,刘玉真,尚振华,李春静.PEG-600在有机合成中的应用及前景[J].河北化工,2006,29(10):4-7. 被引量:4
  • 4DE COR, DE JON, HEE, et al. Preparation of arylaminopyrimidinas as inhibitors of HIV replication: WO, 2000/027825 [P] .2000 - 05 - 18.
  • 5DON W, LUD, DE COR, et al. Evolution of anti-HIV drug canditates. Part 3 : diarylpyrimidine (DAPY) analogues [ J ]. Bio Med Chem Lett, 2001, 11(17) : 2235 - 2239.
  • 6US FDA. FDA hbelling information[ EB/OL]. [2008 - 01 - 18]. http://www. fda. gov/cder/foi/label/2008/0221871b1.pdf.
  • 7JOS V M, PED C, BEA G, et al. Efficacy and safety of TMC125(etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial [J ]. The Lancet, 2007, 370 (9581) : 29 - 38.
  • 8ADR L, THO C, BON C, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial [J ]. The Lancet, 2007, 370 ( 9581 ) : 39 - 48.
  • 9CAMP1AN| G, RAMUNNO A, MAGA G, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives[J]. Curt Pharm Des, 2002, 8(8): 615 -657.
  • 10SLUIS-CREMER N, TEMIZ NA, BAHAR I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding[ J]. Curr HIV Res, 2004,2(4): 323-332.

共引文献24

同被引文献35

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部